Menu Search
Equities

Vivani Medical Inc

U5P:MUN

Vivani Medical Inc

Actions
  • Price (EUR)1.72
  • Today's Change0.04 / 2.38%
  • Shares traded5.80k
  • 1 Year change+42.15%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.

  • Revenue in USD (TTM)0.00
  • Net income in USD-25.65m
  • Incorporated2003
  • Employees44.00
  • Location
    Vivani Medical Inc1350 S. LOOP ROADALAMEDA 94502United StatesUSA
  • Phone+1 (818) 833-5000
  • Fax+1 (818) 833-5067
  • Websitehttp://www.secondsight.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.